RECOMBINANT PEPTIDES THAT BIND TO A TUMOUR-SPECIFIC ANTIBODY FOR BREAST CANCER AND USE

RECOMBINANT PEPTIDES THAT BIND TO A TUMOUR-SPECIFIC ANTIBODY FOR BREAST CANCER AND USE

The present invention refers to the use of synthetic peptides built from the selection of peptides available on the surface of filamentous phages and that bind to the FabC4 antibody fragment with clinical relevance in the diagnosis of Breast Cancer (BC) and in the prognosis of Triple-Negative Breast...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: VAZ, Emilia Rezende, RIBIERO, Matheus Alves, MOTA, Sara Teixeira Soares, ARAÚJO, Thaise Goncalves De, FILHO, Luiz Ricardo Goulart, VECCHI, Lara, ALVES, Douglas Alexsander, ZOIA, Mariana Alves Pereira, MAIA, Yara Cristina de Paiva, ARAUJO, Galber Rodrigues
Format: Patent
Sprache:eng ; fre ; ger
Schlagworte:
CHEMISTRY
HUMAN NECESSITIES
HYGIENE
INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIRCHEMICAL OR PHYSICAL PROPERTIES
MEASURING
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PEPTIDES
PHYSICS
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
TESTING
Online-Zugang:Volltext bestellen
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:The present invention refers to the use of synthetic peptides built from the selection of peptides available on the surface of filamentous phages and that bind to the FabC4 antibody fragment with clinical relevance in the diagnosis of Breast Cancer (BC) and in the prognosis of Triple-Negative Breast Cancer (TNBC). The peptides were specific to tumor proteins and could be potentially used in immunodiagnostic tests, formulations coupled to fluorescent or radioactive particles for diagnostic imaging, therapeutic drug carriers, and in immunogenic compositions for BC management. The technology used for peptide selection was the peptide expression system on the surface of filamentous bacteriophage. The strategy used was the selection of binding peptides of tumor proteins present in serum from TNBC patients.